Pattern of extranodal involvement and its impact on survival in diffuse large B-cell lymphoma from a tertiary cancer center in rural India.


Journal

Journal of cancer research and therapeutics
ISSN: 1998-4138
Titre abrégé: J Cancer Res Ther
Pays: India
ID NLM: 101249598

Informations de publication

Date de publication:
Historique:
entrez: 16 9 2021
pubmed: 17 9 2021
medline: 27 1 2022
Statut: ppublish

Résumé

Extranodal (EN) involvement in diffuse large B-cell lymphoma (DLBCL) carries poor prognosis. Both the number and the specific sites of EN involvement are important in predicting prognosis. Given that the epidemiologic pattern of DLBCL in India is different from the rest of the world and such data correlations are scarce from developing countries, we aimed to find out if specific site and number of EN involvement could predict survival in DLBCL. Patients with DLBCL treated with combination chemotherapy plus rituximab were included. Site and number of EN involvement were noted. Univariate analysis for survival was performed for EN involvement or not, specific site of involvement, and number of EN involvement (0/1 vs. ≥2). Among a total of 177 patients, 92 (52%) patients had EN disease. When patients with 2 or more EN sites were compared against patients with 0 or 1 site, there was significant reduction in both progression-free survival (PFS) and overall survival (OS) (3-year OS of 55% vs. 79%, P = 0.001, 3-year PFS of 42% vs. 65%, P = 0.001). When specific EN sites were studied for correlation with survival, involvement of skin/soft tissue, and serosa were associated with significant reduction in 3-year OS (33% vs. 74%, P = 0.011, and 63% vs. 75%, P = 0.03, respectively) and 3-year PFS (25% vs. 62%, P < 0.001, and 46% vs. 62%, P = 0.01, respectively). Two or more EN sites in DLBCL predicted inferior survival. Serosal and skin/soft tissue involvement also predicted poor survival.

Identifiants

pubmed: 34528545
pii: JCanResTher_2021_17_4_938_298616
doi: 10.4103/jcrt.JCRT_428_19
doi:

Substances chimiques

Rituximab 4F4X42SYQ6
Vincristine 5J49Q6B70F
Doxorubicin 80168379AG
Cyclophosphamide 8N3DW7272P
Prednisone VB0R961HZT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

938-942

Déclaration de conflit d'intérêts

None

Auteurs

Chandran K Nair (CK)

Department of Clinical Hematology and Medical Oncology, Malabar Cancer Centre, Kannur, Kerala, India.

Anju R Kurup (AR)

Department of Clinical Hematology and Medical Oncology, Malabar Cancer Centre, Kannur, Kerala, India.

A Manuprasad (A)

Department of Clinical Hematology and Medical Oncology, Malabar Cancer Centre, Kannur, Kerala, India.

Praveen Kumar Shenoy (PK)

Department of Clinical Hematology and Medical Oncology, Malabar Cancer Centre, Kannur, Kerala, India.

Vineetha Raghavan (V)

Department of Clinical Hematology and Medical Oncology, Malabar Cancer Centre, Kannur, Kerala, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH